Is Venus Remedies a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Venus Remedies Ltd is a average quality company .

Is Venus Remedies undervalued or overvalued?

The key valuation ratios of Venus Remedies Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Venus Remedies share price return in the past 10 years?

Venus Remedies Ltd share price has appreciated 2.3% annually (CAGR) over the past ten years.

Is Venus Remedies a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Venus Remedies Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

Venus Remedies Ltd - Stock Valuation and Financial Performance

Name: Venus Remedies
Brand: Venus Remedies

BSE: 526953 | NSE: VENUSREM | Pharmaceuticals & Drugs | Small Cap

Place order

Venus Remedies Share Price

₹299.90 5.40 1.83%
as on 21-Nov'24 16:59

10 Year X-Ray of Venus Remedies:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	5.7%	5.4%	2%	1.2%	-0.7%	0.9%	12.4%	7.9%	7.7%	8.7%	-
Value Creation Index ⓘ	-0.6	-0.6	-0.9	-0.9	-1.1	-0.9	-0.1	-0.4	-0.5	-0.4	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	464	418	400	372	322	339	548	600	556	601	615
Sales YoY Gr.	-	-9.9%	-4.4%	-6.9%	-13.6%	5.4%	61.5%	9.5%	-7.4%	8.3%	-
Adj EPS ⓘ	4.4	1.5	-15	-24.9	-20.1	-4.6	33.1	27.1	16	18.2	16.5
YoY Gr.	-	-66.9%	-1121.8%	NA	NA	NA	NA	-18%	-40.8%	13.5%	-
BVPS (₹) ⓘ	399.1	382.5	314.9	293.2	269.4	262	313.2	329.5	344.4	364.7	369.7
Adj Net Profit ⓘ	5.1	1.7	-18.5	-30.8	-24.8	-5.7	40.8	36.2	21.4	24.3	22
Cash Flow from Ops. ⓘ	67.8	46.9	58.9	31.2	45.3	77.6	132	41.1	36.6	37.3	-
Debt/CF from Ops. ⓘ	4.7	7.2	5.3	9.8	6.6	2.8	0.4	1	1.2	1.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	2.9%	13.3%	3.1%	8.3%
Adj EPS ⓘ	17%	NA	-18.1%	13.5%
BVPSⓘ	-1%	6.3%	5.2%	5.9%
Share Price	2.3%	67.3%	-11.1%	-17.6%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	1.1	0.4	-4.5	-8.2	-7.1	-1.7	11.3	8.6	4.8	5.1	4.5
Op. Profit Mgn % ⓘ	19.2	19.4	12.7	10.6	10.1	12	9.8	10.4	10.8	9.9	7.8
Net Profit Mgn % ⓘ	1.1	0.4	-4.6	-8.3	-7.7	-1.7	7.5	6	3.9	4	3.6
Debt to Equity ⓘ	0.7	0.8	0.8	0.9	0.9	0.7	0.1	0.1	0.1	0.1	0.1
Working Cap Days ⓘ	251	270	270	285	337	338	188	152	180	177	94
Cash Conv. Cycle ⓘ	135	153	152	153	170	147	70	56	83	90	71

Recent Performance Summary

Sales growth is good in last 4 quarters at 15.52%

Return on Equity has declined versus last 3 years average to 4.50%

Sales growth has been subdued in last 3 years 3.14%

Net Profit has been subdued in last 3 years -18.05%

Latest Financials - Venus Remedies Ltd.

	Standalone	Consolidated
TTM EPS (₹)	25.7	16.5
TTM Sales (₹ Cr.)	579	615
BVPS (₹.) ⓘ	392.5	369.7
Reserves (₹ Cr.) ⓘ	511	481
P/BV ⓘ	0.75	0.80
PE ⓘ	11.44	17.82

From the Market
52 Week Low / High (₹)	280.00 / 429.60
All Time Low / High (₹)	1.00 / 638.50
Market Cap (₹ Cr.)	394
Equity (₹ Cr.)	13.4
Face Value (₹)	10
Industry PE ⓘ	43

Management X-Ray of Venus Remedies:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Venus Remedies

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Venus Remedies

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	464	418	400	372	322	339	548	600	556	601
Operating Expenses ⓘ	375	337	349	333	289	299	494	538	495	542
Manufacturing Costs	21	20	47	40	26	26	27	36	38	35
Material Costs	269	239	227	205	182	174	341	387	331	355
Employee Cost	32	32	34	39	42	46	46	52	57	67
Other Costs ⓘ	52	46	41	48	39	53	80	62	70	85
Operating Profit ⓘ	89	81	51	39	33	41	54	62	60	60
Operating Profit Margin (%)	19.2%	19.4%	12.7%	10.6%	10.1%	12.0%	9.8%	10.3%	10.8%	9.9%
Other Income ⓘ	1	2	4	2	6	5	20	8	10	12
Interest ⓘ	41	38	36	36	25	13	13	0	0	0
Depreciation ⓘ	46	42	40	34	34	32	35	34	32	26
Exceptional Items ⓘ	0	0	0	0	-9	-9	23	0	0	0
Profit Before Tax ⓘ	3	4	-22	-28	-30	-8	49	36	38	45
Tax ⓘ	-3	2	-5	3	-1	2	-13	-4	11	16
Profit After Tax	5	2	-17	-31	-29	-10	62	41	27	28
PAT Margin (%)	1.1%	0.4%	-4.3%	-8.2%	-8.9%	-2.9%	11.3%	6.8%	4.8%	4.7%
Adjusted EPS (₹)	4.5	1.5	-13.8	-24.9	-23.2	-8.1	50.0	30.5	19.9	21.3
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	457	438	389	362	333	323	387	440	460	488
Share Capital ⓘ	11	11	12	12	12	12	12	13	13	13
Reserves ⓘ	445	426	376	350	320	311	374	427	447	474
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	318	314	281	259	229	158	51	43	42	41
Long Term Debt	202	191	162	137	116	72	47	39	39	39
Short Term Debt	115	123	119	121	113	86	4	4	4	3
Trade Payables	30	25	30	29	36	37	71	50	51	44
Others Liabilities ⓘ	37	66	66	101	135	126	47	46	48	54
Total Liabilities ⓘ	841	843	765	751	733	644	556	579	601	627
Fixed Assets
Gross Block	641	680	687	703	707	624	616	613	604	618
Accumulated Depreciation	197	227	280	314	343	335	355	372	388	399
Net Fixed Assetsⓘ	444	452	406	389	364	289	262	241	216	219
CWIP ⓘ	78	80	66	65	65	25	25	25	26	21
Investmentsⓘ	0	0	0	0	0	0	0	0	20	19
Inventories	143	143	141	138	143	141	120	126	120	122
Trade Receivables	63	62	47	47	38	31	32	39	77	80
Cash Equivalents	4	7	4	4	3	2	31	50	54	68
Others Assetsⓘ	109	98	101	107	120	156	86	98	88	98
Total Assets ⓘ	841	843	765	751	733	644	556	579	601	627

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	68	47	59	31	45	78	132	41	37	37
PBT ⓘ	3	4	-22	-28	-21	1	25	36	38	45
Adjustment ⓘ	84	56	71	66	61	42	22	26	23	20
Changes in Working Capital ⓘ	-18	-13	10	-8	5	21	61	-22	-25	-12
Tax Paid ⓘ	0	0	0	0	0	0	0	0	0	-15
Cash Flow From Investing Activity ⓘ	-67	3	-18	-11	-11	-5	56	-17	-51	-7
Capex	0	0	-23	0	-10	-8	58	-13	-8	-13
Net Investments	0	0	0	0	0	0	-2	-5	-45	1
Others ⓘ	-67	3	4	-11	-1	3	1	1	2	5
Cash Flow From Financing Activityⓘ	-1	-46	-44	-39	-35	-73	-162	-9	-1	-1
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	29	-11	-12	-9	-5	-34	-88	-9	0	-1
Interest Paid ⓘ	-35	-35	-33	-32	-22	-12	-7	0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	5	0	1	2	-8	-28	-68	0	0	0
Net Cash Flow ⓘ	-1	3	-4	-20	-1	0	26	15	-15	29

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	1.12	0.38	-4.13	-8.18	-8.23	-3.05	17.4	9.85	5.9	6.01
ROCE (%)	5.74	5.35	2	1.17	-0.67	0.9	12.37	7.89	7.72	8.67
Asset Turnover Ratio	0.55	0.5	0.5	0.49	0.43	0.49	0.91	1.06	0.94	0.98
PAT to CFO Conversion(x)	13.6	23.5	N/A	N/A	N/A	N/A	2.13	1	1.37	1.32
Working Capital Days
Receivable Days	50	54	50	46	48	37	21	21	38	48
Inventory Days	112	125	130	137	159	153	87	75	81	73
Payable Days	41	42	44	53	66	76	58	57	56	49

Venus Remedies Ltd Stock News

Venus Remedies Ltd FAQs

What is the share price of Venus Remedies?

Company share prices are keep on changing according to the market conditions. The closing price of Venus Remedies on 21-Nov-2024 16:59 is ₹299.9.

What is the market cap of Venus Remedies?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:59 the market cap of Venus Remedies stood at ₹393.7.

What is the P/E ratio of Venus Remedies?

The latest P/E ratio of Venus Remedies as of 21-Nov-2024 16:59 is 11.44.

What is the P/B ratio of Venus Remedies?

The latest P/B ratio of Venus Remedies as of 21-Nov-2024 16:59 is 0.75.

What is the 52-week high and low of Venus Remedies?

The 52-week high of Venus Remedies is ₹429.6 and the 52-week low is ₹280.0.

What is the TTM revenue of Venus Remedies?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Venus Remedies is ₹579.3 ( Cr.) .

About Venus Remedies Ltd

Venus Remedies incorporated in 1989, is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics.

Company has two manufacturing facilities located in India and Germany. Company manufactures Oncological and Cefelosporine Injectable products.

Its manufacturing facility located in India has received ISO 9001, ISO, 14001 and OHSAS 18001 for quality management. Its Germany facility follows EU-GMP norms.

Presently, the company has successfully made its presence in the markets of Philippines, Thailand, Malaysia, Cambodia, Burma, Vietnam, Sri Lanka, Pakistan, Bangladesh, Nepal, Uganda, Kenya, Botswana, Zimbabwe, Sudan, Mauritius, Yemen, Iraq, Russia, Belarus, Ukraine, Costa Rica, Venezuela, Guatemala, Peru, Colombia, Ecuador, Syria, Yeman, Togo, Saudi Arbia and Iraq.

Company has entered into strategic alliances with various pharmaceutical companies to launch its R&D based specialty products. It has tie-ups with companies namely IPCA Laboratories, Elder Pharmaceuticals, Shreya Lifesciences, Cadila Healthcare, Glenmark Pharmaceuticals, Marksans Pharma, Indoco Remedies, Karle Health Sciences, Lupin and Jagsonpal Pharmaceuticals.

Company also conducts in-house research and development activities that focuses Formulation Development, NDDS (Novel Drug Delivery System), new formulations of off patented chemicals and analytical and chemical research.

Products

The company is engaged in manufacturing products catering various segments such as Oncology, Cephalosporins, Carbapenems and Other Specialties, Intravenous Products, Vials/Lyophilized Injectables, Pre-Filled Syringes, Hormones, Ampoules and Biological Products.

Milestone/ Awards

2009
Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa.
Venus Bags Another Product Patent from South Africa for POTENTOX.
2010
Venus Remedies receives GMP Certification from Botswana".
Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits.
The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015.
Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent"
2011
Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011.
Venus launches its patented research product ACHNILâ€ in India.
Venus Remedies wins ""India Manufacturing Excellence Award 2011.
2012
Venus Remedies introduces "Ready-to-Use"" Single Vial Taxedol in India
Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India
The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012.
Venus wins Patent award in Silver Category.